STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Mirum Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) filed a Form 144 reporting the proposed sale of 40,000 common shares acquired by stock option exercise on 08/11/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,480,000 based on the filing and the company has 50,237,647 shares outstanding as shown.

The filing also records a prior sale during the past three months: Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040. The filer certifies they have no undisclosed material adverse information and notes the securities were paid for in cash at acquisition.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider notice for 40,000 shares (~0.08% of outstanding) from an option exercise; transaction size appears modest relative to company equity.

The Form 144 documents a proposed sale of 40,000 common shares acquired on 08/11/2025 via a stock option exercise, to be brokered by Morgan Stanley Smith Barney. The filing lists an aggregate market value of $2,480,000 and total shares outstanding of 50,237,647. From a capital-markets perspective, this represents a small percentage of the company's float, limiting likely market impact. The disclosure of a prior 40,000-share sale on 08/07/2025 for $2,210,040 provides recent pricing context. The form’s attestation about no undisclosed material information is standard.

TL;DR: Routine insider sale notice; compliance with Rule 144 is documented and the filer affirms no undisclosed material information.

The submission is a standard Rule 144 notice disclosing an insider-related sale following a stock option exercise. It names the executing broker and records a recent related sale by Christopher Peetz. The form includes the required attestation regarding material nonpublic information and notes cash payment at acquisition. From a governance standpoint, the filing satisfies disclosure obligations; no governance irregularities are evident in the document itself.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Mirum (MIRM) Form 144 report?

The Form 144 reports a proposed sale of 40,000 common shares acquired via a stock option exercise on 08/11/2025, to be sold through Morgan Stanley Smith Barney LLC.

What is the aggregate market value and outstanding share count disclosed?

The filing lists an aggregate market value of $2,480,000 for the shares to be sold and reports 50,237,647 shares outstanding.

Was there any related sale in the past three months for MIRM?

Yes. The filing shows Christopher Peetz sold 40,000 shares on 08/07/2025 for $2,210,040.

How were the acquired shares paid for according to the filing?

The securities acquired on 08/11/2025 were paid for in cash, following a stock option exercise.

Does the filer attest to possession of any undisclosed material information?

Yes. The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Mirum Pharmaceuticals

NASDAQ:MIRM

MIRM Rankings

MIRM Latest News

MIRM Latest SEC Filings

MIRM Stock Data

3.71B
43.41M
1.86%
114.06%
13.66%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY